MannKind

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MannKind and other ETFs, options, and stocks.

About MNKD

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501.

CEO

Michael E. Castagna

CEOMichael E. Castagna

Employees

592

Employees592

Headquarters

Danbury, Connecticut

HeadquartersDanbury, Connecticut

Founded

1991

Founded1991

Employees

592

Employees592

MNKD Key Statistics

Market cap

1.17B

Market cap1.17B

Price-Earnings ratio

-48.33

Price-Earnings ratio-48.33

Dividend yield

—

Dividend yield—

Average volume

6.06M

Average volume6.06M

High today

$3.94

High today$3.94

Low today

$3.51

Low today$3.51

Open price

$3.67

Open price$3.67

Volume

20.39M

Volume20.39M

52 Week high

$6.51

52 Week high$6.51

52 Week low

$2.23

52 Week low$2.23

Stock Snapshot

The current MannKind(MNKD) stock price is $3.75, with a market capitalization of 1.17B. The stock trades at a price-to-earnings (P/E) ratio of -48.33.

During the trading session on 2026-05-31, MannKind(MNKD) shares reached a daily high of $3.94 and a low of $3.51. At a current price of $3.75, the stock is +6.8% higher than the low and still -4.8% under the high.

Trading activity shows a volume of 20.39M, compared to an average daily volume of 6.06M.

Over the past 52 weeks, MannKind(MNKD) stock has traded between a high of $6.51 and a low of $2.23.

MNKD News

CBS News 2d

Pennsylvania teen part of trial as FDA approves needle-free insulin for kids with diabetes: "It's pretty cool" - CBS News

...

Simply Wall St 2d

MannKind Is Up 10.0% After FDA Drops Afrezza Lung Cancer Trial Requirement – What’s Changed

In late May 2026, MannKind Corporation disclosed that the FDA has released it from a large, long-planned postmarketing lung cancer risk trial for Afrezza, leavi...

TipRanks 2d

MannKind announces FDA approval of Afrezza for use in children aged 6 and older

MannKind (MNKD) announced that the U.S. Food and Drug Administration has approved Afrezza Inhalation Powder for use in children and adolescents aged 6 and older...

Analyst ratings

88%

of 8 ratings

Buy

87.5%

Hold

12.5%

Sell

More MNKD News

TipRanks 3d

MannKind Released From Major Afrezza Trial Obligation

Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-co...

Simply Wall St 6d

Is It Time To Reassess MannKind After The Recent Share Price Rebound

Wondering whether MannKind's current share price lines up with its underlying worth, or if the market is mispricing the stock. The stock last closed at US$3.38...

People also own

Based on the portfolios of people who own MNKD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.